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An association between epilepsy and reproductive distur-
bances with an apparent increase in a polycystic ovarian syn-
drome (PCOS) has been reported. Whether this association
can be attributed to epilepsy itself or is related to antiepileptic
drug therapy, in particular valproate (VPA), remains contro-
versial. We studied effects of a long-term VPA treatment on
cycling monkeys, postulating that, if VPA monotherapy were
to promote abnormal endocrine and metabolic parameters
that are characteristic of PCOS, changes in cyclicity would be
readily demonstrated.
After a 2-month control, a 12- to 15-month VPA mono-
therapy was initiated in 7 regularly cycling rhesus monkeys.
Overall mean levels of VPA were 88.7  4.0 (SE) g/ml. Mean
body weight increased progressively during VPA treatment
from 8.5  0.5 kg before treatment to 9.6  0.7 kg in the last
week of treatment (P < 0.05). Monkeys continued to have reg-
ular ovulatory menstrual cycles throughout VPA mono-
therapy. Length of the cycles was 28  0.58 d in control and
28.4  1.18 d in the last 3 months of VPA treatment. Follicular
and luteal lengths and peak preovulatory estradiol and inte-
grated luteal progesterone levels did not differ between con-
trol and treatment. Ovaries from VPA-treated monkeys
showed histological evidence of ovulation, and none had char-
acteristic features of PCOS. Endocrine PCOS markers, such as
increased early follicular LH/FSH ratio and androgen levels
were not different in control and VPA treatment cycles. LH
and 17-hydroxyprogesterone responses to GnRH agonist chal-
lenges and the insulin response to glucose tolerance tests
were similar in control and VPA groups. Lipid profiles were
not affected by VPA treatment. The data indicate that a 12- to
15-month therapeutic exposure to VPA does not induce cyclic
hormonal or morphological ovarian abnormalities or charac-
teristics of the PCOS when administered to nonepileptic nor-
mally cycling nonhuman primates. (J Clin Endocrinol Metab
88: 2908–2915, 2003)
MENSTRUAL AND REPRODUCTIVE disturbanceshave been reported in women with epilepsy (1–4)
and bipolar disease (5), with an apparent increased finding
of polycystic appearing ovaries and to a lesser degree of a
polycystic ovarian-like syndrome (PCOS; Refs. 1 and 6). One
group of investigators has suggested that these cyclic ab-
normalities are related to a specific antiepileptic drug, val-
proate (VPA), rather than to the brain disorder itself (7, 8).
Some authors have suggested that VPA therapy in women
with epilepsy induces hyperandrogenism (8–10) and a met-
abolic syndrome with centripetal obesity, hyperinsulinemia,
lipid abnormalities, and polycystic appearing ovaries, and
that, therefore, VPA treatment in young women is relatively
contraindicated (11). Other investigators have concluded
that the prevalence of PCOS is increased in epilepsy inde-
pendently of antiepileptic drug treatment, or they contest the
association between epilepsy and PCOS (1, 12, 13). The per-
sisting controversy may reflect the difficulty in separating
menstrual and metabolic disturbances in women with epi-
lepsy from effects of the therapy itself in small clinical series.
It may also mirror the observation that the finding of poly-
cystic ovaries in young women is not unusual, encompassing
as much as 20% of the normal population in some studies
(14).
VPA is a branched fatty acid that has a broad spectrum of
antiepileptic efficacy in the prevention of both partial and
generalized seizures (15). Because this drug is an FDA-
approved treatment for epilepsy, migraine, and bipolar dis-
ease, it is important to determine its potential for inducing
reproductive disturbances. For this reason, we have studied
the effect of a 12- to 15-month VPA treatment in normally
cycling nonhuman primates. We have postulated that if VPA
monotherapy were to promote abnormal endocrine and met-
abolic parameters characteristic of PCOS in these normally
cycling rhesus monkeys, changes in cyclic patterns could be
readily demonstrated. Alternatively, maintenance of normal
reproductive parameters despite this long-term therapy
would substantiate the observation that VPA itself does not
affect reproductive endocrinology in the normal individual.
Materials and Methods
Animals
The experimental protocol was approved by the Animal Care and Use
Committee of Columbia University and was performed in accordance
with the NIH guide for the care and use of laboratory animals. Ten adult
female rhesus monkeys (Macaca mulatta), 11–16 yr of age, were selected
for this experiment. The animals were housed in individual cages in
temperature- and light-controlled (lights on from 0730–1930 h) rooms.
They were fed Purina monkey chow (Ralston-Purina, St. Louis, MO)
Abbreviations: CV, Coefficient(s) of variation; DCL, degenerating
corpora lutea; DHEAS, dehydroepiandrosterone sulfate; NS, not signif-
icant; PCOS, polycystic ovarian syndrome; RCL, recent corpora lutea;
VPA, valproate.
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twice a day and fresh fruit or vegetables. Water was available at all times.
The experiments were conducted between September 2000 and February
2002.
In a preliminary step, we investigated whether each animal had
normal menstrual cycles. Blood samples were obtained daily by veni-
puncture (a process to which the animals had previously been habitu-
ated) for estradiol and progesterone measurements over a period of two
menstrual cycles. Menstruation was determined by daily vaginal swab-
bing. Seven monkeys that showed two normal menstrual cycles, ac-
cording to criteria established previously in our laboratory (see Exper-
imental protocol), were then immediately included in the study. Before the
study, these animals had a mean (se) body weight of 8.5  0.5 kg,
excluding one animal (no. 7) who weighted 14.7 kg.
Experimental protocol
The study was designed to investigate potential effects of long-term
VPA treatment on cyclic ovarian function. The content of four sprinkle
capsules (Depakote Sprinkle capsules, Abbott Laboratories, North Chi-
cago, IL; 125 mg/capsule), mixed with a variety of jams, jellies, and
syrups (changed weekly) and coated on various cookies or fruits, was
given orally twice a day at 0900 and 1600 h; each animal was closely
observed for ingestion. The individual doses as well as total daily dosing
of VPA in this monkey study exceeded on a milligram per kilogram basis
the maximum daily dose recommended in the human (60 mg/kg).
However, because the conversion factor for equieffective individual
doses of VPA in the monkey compared with the human has been re-
ported to be three (16), the daily human therapeutic dose (20 mg/kg) was
multiplied by a factor of three for an equieffective monkey dose of 60
mg/kg. This dose was administered twice daily for a total dose of 120
mg/kgd.
VPA blood levels were measured biweekly throughout the experi-
ment at 1100 h, 2 h after morning drug administration. If VPA blood
levels were less than 60 g/ml or if the animal failed to ingest the
mixture completely, the mix into which the drug was administered was
immediately changed to make it more palatable to that individual an-
imal. The overall course of VPA treatment extended from 12.7–15.7
months.
To determine menstrual cyclicity, menstruation was monitored, and
blood samples were obtained daily for the duration of the treatment.
Hematocrits were verified at frequent intervals; no animals required
supplemental iron therapy. Midcycle peak estradiol levels and daily
levels of progesterone during the entire luteal phase were measured in
each control and treatment cycle. Follicular and luteal phase lengths
were recorded, and the integrated daily progesterone luteal concentra-
tions were calculated. The rise of progesterone above 0.4 ng/ml (coupled
to the preceding decrease in estradiol) was used to mark the beginning
of the luteal phase. To determine whether endpoints relevant to the
development of PCOS were influenced by the experimental therapy,
LH/FSH ratios were determined at monthly intervals on d 1 of each
control and treatment cycle. Ovarian androgens (androstenedione, total
testosterone) were measured in each cycle at their cyclic peak, which
paralleled the time of the estradiol peak, whereas the adrenal androgen
dehydroepiandrosterone sulfate (DHEAS) was measured on d 2 of the
cycle.
At the end of VPA treatment, two tests were performed. For the GnRH
agonist stimulation test, Lupron (Abbott Laboratories, 1 mg) was in-
jected sc on d 1–4 of the cycle. Blood samples were obtained at 30-min
intervals for the first 4 h, then at 6 h and 22 h after injection. The LH and
17-hydroxyprogesterone responses were measured. The glucose toler-
ance test was initiated after a 16-h fasting period. Dextrose (Abbott
Laboratories; 0.1 g/kg) was given iv on d 2–5 of the follicular phase, and
blood samples were taken at 5, 10, 20, and 30 min for glucose and
insulin level measurements. For comparison, seven normally cycling
monkeys (9.5  0.5 kg) from our colony, tested at the same time of the
cycle, served as controls. The lipid profile of each animal was compared
in the control period and in the last month of treatment.
After completion of treatment, all animals were ovariectomized. Both
ovaries were placed in saline, examined grossly to identify corpora lutea
and cystic changes, and photographed. Each ovary was then bisected.
Half of the ovary was fixed in a 10% formaldehyde solution. The tissue
was then dehydrated in alcohol, embedded in paraffin, sectioned at 5
m, and mounted serially. The histological sections were stained with
hematoxylin-eosin and examined under the microscope. The other half
of the ovary was frozen and stored at 80 C for potential future analysis.
Assays and statistical analysis
Serum estradiol, progesterone, testosterone, insulin, and VPA were
measured by commercial chemiluminescent immunoassays using the
Immulite system (Diagnostic Products Corp., Los Angeles, CA). Intra-
and interassay coefficients of variation (CV) were 9.3% and 10.5% for
estradiol, 6.6% and 7.9% for progesterone, 7.4% and 9.8% for testoster-
one, 4.7% and 8.2% for insulin, and 3.8% and 9.5% for VPA, respectively.
LH and FSH levels were measured by in-house recombinant homolo-
gous RIA (17, 18). Intra- and interassay CV were 7.9% and 13.1% for LH
and 5.0% and 6.1% for FSH, respectively. Androstenedione and 17-
hydroxyprogesterone were measured by ELISA (Diagnostic Systems
Laboratories, Inc., Webster, TX). Intra- and interassay CV were 2.4% and
8.0% for androstenedione and 2.1% and 8.8% for 17-hydroxyprogest-
erone, respectively. DHEAS was measured by a commercial RIA (Coat-
A-Count, Diagnostic Products Corp.), with an intra- and interassay CV
of 5.9% and 8.2%, respectively. Glucose levels were measured by a blood
glucose testing system (Precision G, Abbott Diagnostic Laboratories,
Bedford, MA). Enzymatic tests (Roche Diagnostics, Indianapolis, IN)
were used to measure serum total cholesterol, high-density lipoprotein
cholesterol after precipitation, low-density lipoprotein cholesterol and
triglycerides, the latter after lipase hydrolysis.
Cycle parameters, such as the length of the follicular and luteal
phases, hormone concentrations, as well as luteal function as reflected
by integrated progesterone values in the luteal phase, were compared
in the control, first and last trimester of treatment. For luteal proges-
terone evaluation, the areas under the luteal phase progesterone curves
(from the day of LH surge 1 to the day of menstruation 1) were
calculated by trapezoidal analysis. Insulin sensitivity after long-term
VPA treatment was evaluated using fasting glucose and insulin levels
by the quantitative insulin sensitivity check index method (19) as fol-
lows: 1/[log(insulin U/ml)  log(glucose mg/dl)].
Comparisons were made by multiple ANOVA followed by the Tukey
test. Paired Student’s t tests were used for the comparison of body
weights before and after VPA treatment. The level of significance was
established at P less than 0.05.
Results
Overall mean levels of VPA were 88.7  4.0 g/ml, as
measured 2 h after morning drug administration, with the
mean (se) for the seven individual monkeys as follows: 97.6
(5.1), 97.7 (6.7), 102.2 (4.4), 75.4 (3.1), 87.8(5.7), 83.5
(3.7), and 77.8 (6.0) g/ml. [According to the manufac-
turer’s description of the drug, as outlined in the Physicians
Desk Reference, the therapeutic range in epilepsy is com-
TABLE 1. Cyclic parameters in VPA-treated monkeys (mean  SE)
Mean of 2 control
cycles
Mean of first 3
treatment cycles
Mean of last 3
treatment cycles
Mean of overall treatment
cycles
Follicular length (d) 12.4  0.59 12.8  0.46 12.2  0.46 12.8  0.28
Estradiol peak (pg/ml) 217.1  22.3 241.8  22.89 161.8  16.7 246.9  7.25
Luteal length (d) 15.3  0.24 15.4  0.20 14.8  0.70 15.5  0.13
Integrated progesterone (ng/ml) 46.2  0.88 46.4  1.63 46.7  2.51 48.5  4.26
LH/FSH ratio in early follicular phase 0.59  0.05 0.58  0.03 0.66  0.04 0.64  0.03
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monly considered to be 50–100 g/ml]. Because peak VPA
concentrations are reported to occur at 1.2 h after oral ad-
ministration of 100 mg/kg in the monkey (20), our peak
levels were most likely higher.
Mean (se) body weight in six of the seven animals in-
creased progressively during treatment with VPA from 8.5 
0.5 kg before treatment began to 8.5  1.0 after 3 months of
treatment, 9.2  0.6 after 9 months, and 9.6  0.7 kg in the
last week of treatment (P  0.05 vs. pretreatment). Body
weight in monkey 7 was 14.2 kg in the last week of treatment
vs. 14.7 kg before treatment.
Menstrual cyclicity
All monkeys, except one, continued to have regular ovu-
latory menstrual cycles throughout VPA monotherapy. One
exception to that pattern was monkey 4JU who, after three
regular menstrual cycles during the first 3 months of treat-
ment, had a 102-d amenorrheic period that terminated in a
normal ovulatory cycle. After this period, she resumed nor-
mal-length cycles. Overall mean (se) length of menstrual
cycles was 28  0.58 d in control cycles, 28.1  0.54 d in the
first 3 months of treatment, and 28.4  1.18 d in the last 3
FIG. 1. Effects of VPA treatment on the menstrual cycle, as illustrated by daily estradiol levels in the follicular phase (lines) and by daily
progesterone levels in the luteal phase (shaded areas) in an individual monkey (no. 89N111). Two control cycles were first documented, starting
on 9/15/00. VPA treatment was started at the arrow and continued until 2/7/02. Data are continuous from levels 1–3. The data indicate that
long-term VPA therapy does not interfere with the normal menstrual cycle.
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months of treatment. Mean follicular and luteal length did
not differ between the control period and the first and last
trimesters of the treatment (Table 1). Similarly, peak pre-
ovulatory estradiol levels and integrated luteal progesterone
were similar in all groups (Table 1). One monkey (no. 7) had
a significant decrease in integrated luteal progesterone levels
during the months of May to September only (33.3  1.5 vs.
48.3  2.3 ng/ml), a phenomenon that occurs spontaneously
in about 10–15% of the animals in our colony during the
summer months. Early follicular phase LH/FSH ratios were
similar in control and treatment cycles (Table 1). Figure 1
illustrates daily follicular estradiol and luteal progesterone
levels in successive control (September and October 2000)
and treatment cycles (November 2000 to February 2002) in an
individual monkey.
Baseline and stimulated hormone levels
Figure 2 compares mean LH levels on d 2 of the cycle and
mean testosterone levels measured on the day of the pre-
ovulatory estradiol peak in control cycles and in the first,
second, and last trimesters of VPA treatment. No significant
difference was observed. Figure 3 compares mean DHEAS
and androstenedione levels before and during VPA treat-
ment. Although there was a tendency for the levels to
decrease with treatment, the decrease was not significant.
Figure 4 compares the mean LH (top left panel) and
17-hydroxyprogesterone (top right panel) responses to a
GnRH agonist challenge test in control and VPA-treated
monkeys. Although LH was significantly increased 22 h after
the agonist administration, there was no difference between
the control and VPA-treated groups. No significant differ-
ences were observed in regard to 17-hydroxyprogesterone.
Figure 4 (bottom) illustrates glucose levels (left panel) and the
insulin response (right panel) to a glucose tolerance test. No
significant differences were observed between VPA-treated
and control groups. Quantitative insulin sensitivity check
index values were 0.3057  0.0037 and 0.3050  0.004 in
control and VPA-treated animals, respectively, and were not
significantly different. Mean ( se) total cholesterol was
204.9  9.4 and 188.4  10.3 mg/dl before and at the end of
VPA treatment [not significant (NS)], respectively; high-
density lipoprotein cholesterol was 88.0  6.3 and 88.2  4.3
mg/dl (NS); low-density lipoprotein cholesterol was 100.6 
6.2 and 88.1  9.5 mg/dl (NS); and triglycerides were 81.0 
22.6 and 93.3  16.5 ng/dl (NS).
Ovarian histology
All 14 ovaries from the 7 VPA-treated monkeys were re-
viewed on gross and microscopic examinations. Ovaries
measured from 1.0  0.7  0.5 cm to 2.2  0.8  0.7 cm. The
characteristic histological features of PCOS in humans (mul-
tiple superficial cortical cysts and a region of subcortical
stromal fibrosis resulting in the appearance of a white cap-
sule) were not identified in any of the ovaries (Fig. 5). In
addition, in humans with PCOS, the central portion of the
ovarian cortex usually consists of a homogenous stroma that
lacks stigmata of ovulation, such as corpora lutea or corpora
albicantia. All 14 ovaries from the VPA-treated monkeys
showed histological evidence of ovulation. Table 2 illustrates
histological landmarks in each ovary as well as the hormonal
background at that time. Recent corpora lutea (RCL) were
identified in five of seven monkeys, whereas degenerating
corpora lutea (DCL) and/or corpora albicantia were seen in
all ovaries. Numerous primordial follicles were present in all
ovaries. Developing follicles, including preantral and antral
follicles, were identified in all ovaries. Figure 6 shows a
section of the whole ovary in monkey 53-124 treated with
VPA for 477 d. Note the recently matured corpus luteum and
developing follicles at different stages present in the back-
ground. No hyperthecosis was observed.
Discussion
PCOS is a multisymptomatic disease that includes ovula-
tory dysfunction, hyperandrogenemia, insulin resistance,
and the presence of polycystic ovaries (21, 22). Several stud-
ies have described an association between epilepsy and a
PCOS in women under treatment with various antiepileptic
medications, although no study has been specifically de-
signed to diagnose the syndrome (1–3). One possibility ex-
plaining this association is that the seizure disorder itself
increases the risk of PCOS (4, 12). This hypothesis is sup-
ported by observations of an increased incidence of poly-
FIG. 2. Mean (SE) total testosterone and LH levels before treatment
and during the first to last trimesters of VPA treatment. There were
no significant differences between pretreatment controls and treated
groups.
FIG. 3. Mean (SE) DHEAS and androstenedione levels before treat-
ment and during the first to last trimesters of VPA treatment. No
significant differences were observed between pretreatment controls
and treated groups.
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cystic appearing ovaries in unmedicated epileptic women (1)
or in treated women with epilepsy regardless of the anti-
epileptic therapy (6). Another possibility is that the antiepi-
leptic treatment induces PCOS, and that this is most likely to
arise with VPA. One hypothesis is that certain brain disor-
ders, such as epilepsy and bipolar disease, are associated
with disruption of the hypothalamic pituitary axis and with
menstrual disturbance and anovulatory cycles, whereas VPA
causes hyperandrogenism and carbohydrate intolerance (4,
10, 23). Women with specific brain disorders on VPA may
present with a syndrome very closely resembling PCOS (8,
11). Other groups argue that there is no association between
VPA and any reproductive or metabolic health disorder (1,
12, 24), and it has been suggested that other possible caus-
ative factors may be implicated in the genesis of PCOS (13).
The purpose of our study was to investigate prospectively on
a day-to-day basis whether any of the symptoms associated
with PCOS can be elicited in normal monkeys by a prolonged
VPA treatment.
Disorders of the menstrual cycle, including menstrual cy-
cle irregularities, ovulatory dysfunction, and amenorrhea,
are the most common finding associated with PCOS (21).
These have also been described in women with epilepsy,
with the highest frequency of anovulatory cycles in women
with primary (idiopathic) generalized epilepsy receiving
VPA. Hyperandrogenemia has also been consistently de-
scribed in women with epilepsy receiving VPA for epilepsy
as well as bipolar disease (5, 8, 9, 11, 25). However, our data
clearly demonstrate that prolonged VPA treatment in normal
monkeys with regular menstrual cycles neither induces cy-
clic irregularities nor results in anovulation or amenorrhea.
Regular cycles and appropriate hormone levels were mon-
itored on a daily basis over the entire control and treatment
periods, which lasted from 12.7–15.7 months. The estradiol
profiles characteristic of normal follicular development, as
well as progesterone secretion representative of the normal
corpus luteum, remained cyclic and within normal limits.
PCOS is also characterized by major hormonal dysfunc-
tion. In a majority of patients, PCOS is accompanied by an
increase in GnRH pulse frequency (26, 27), and, because the
increased GnRH pulse generator frequency enhances the
synthesis of LH over that of FSH (28), PCOS women pref-
erentially secrete LH over FSH and show a typical increased
LH/FSH ratio (29). Although experiments have shown that
an acceleration of GnRH pulse frequency readily increases
the LH/FSH ratio in the monkey (30), no significant increase
in this ratio was observed in our animals treated with VPA.
Furthermore, the increase in LH after GnRH agonist stimu-
lation was similar in the control and VPA-treated groups, in
contrast to the response in women with PCOS where it is
enhanced (31). A prime characteristic of PCOS is hyperan-
drogenism (22). Measurements of testosterone were per-
FIG. 4. Top, GnRH challenge test: mean (SE) LH (left panel) and 17-hydroxyprogesterone (right panel) responses to sc administration of the
GnRH antagonist Lupron (1 mg) on d 2–4 of the cycle in control (open squares) and in VPA-treated monkeys (closed squares). *, P  0.05 vs.
baseline. There was no significant difference in the overall response between the control and VPA-treated groups. Bottom, Glucose tolerance
test: mean (SE) glucose (left panel) and insulin (right panel) responses to a glucose tolerance test in control (open squares) and VPA-treated
(closed squares) monkeys. After a 16-h fasting, dextrose (0.1 g/kg) was given iv on d 2–5 of the cycle. Responses in the control and VPA-treated
groups were not significantly different.
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formed at the time of the preovulatory estradiol peak in each
control and treatment cycle, but there were no significant
changes between pretreatment and early or late treatment
samples. Functional ovarian hyperandrogenism in PCOS
women is also characterized by 17-hydroxyprogesterone and
androstenedione hyperresponsiveness to GnRH stimulation
(32, 33). However, the response in the VPA-treated animals
was not different from that in controls. Although not sig-
nificant, there was a tendency for DHEAS, an androgen
produced by the adrenals, to decrease over time during treat-
ment. A similar tendency was seen for androstenedione.
Previous reports have indicated a significant decrease in
DHEAS within 3 months of VPA treatment in female but, not
in male, epileptic patients (34, 35).
Ovarian morphology in PCOS is characterized by cortical
thickening, subcapsular follicular cysts, hyperplastic theca
interna, and stromal hyperplasia (21). In our animals, the
ovaries were removed at the end of the 12.7- to 15.7-month
VPA therapy, and no such changes were observed in any of
the 14 ovaries that were removed. In fact, all ovaries dem-
FIG. 5. Gross view of two pairs of ovaries obtained from monkeys that had been treated for 477 and 438 d with VPA. One pair (no. 53-124) shows
a RCL and the other a DCL (no. 4JU). Both pairs lack a dense fibrous capsule and multiple subcortical ovarian cysts (the typical features of
PCOS).
TABLE 2. Cyclic hormonal status of each ovary at the end of VPA treatment
Monkey Cycle day E2 (pg/ml)
Prog
(ng/ml) Days of treatment Corpus luteum dating Follicle dating
88N182 21 76 1.7 436 RCL (POD 10–12) –
– –
4JU 7 49 0.2 438 DCL DF
DCL –
626 17 37 0.7 386 DCL –
RCL (POD 2–3) –
7 12 75 0.2 480 DCL DF
DCL –
89N111 20 20 5.2 421 RCL (POD 10–12) –
– –
89D361 22 20 0.5 416 RCL (POD 13–14) –
– –
53-124 20 20 2.5 477 RCL (POD 10–12) –
– –
E2, Estradiol; Prog, progesterone; POD, post ovulation day; DF, dominant follicle.
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onstrated normal cyclic histological features, including an-
tral and mature follicles and active corpora lutea, in accord
with the stage of the cycle when they were removed (36). This
is notwithstanding previous observations that polycystic
ovarian characteristics can readily be induced in the rhesus
monkey experimentally, for instance after prenatal androgen
treatment (37) or after active immunization to estradiol (38).
In contrast to the nonhuman primate, a 3-month VPA treat-
ment in the rat was reported to result in a dose-dependent
increase in the number of ovarian follicular cysts and reduc-
tion in the number of corpora lutea (39). However, the ab-
sence of concomitant increases in LH, androgens, and insulin
in these animals suggests a different mechanism of action
than that responsible for PCOS and a possible direct effect of
VPA at higher doses on the ovary in this species (7, 40). Such
a direct effect on the ovary was not observed in our animals.
A side effect of VPA therapy observed in six of our seven
animals was a significant increase in body weight, in the
presence of normal glucose tolerance tests. This increase
became significant after 9 months of VPA therapy. This
change in body weight may not be surprising because the use
of VPA has been previously reported to induce weight gain
(41, 42). The mechanisms leading to weight gain during VPA
medication are, however, still unknown. In women with
epilepsy, this VPA-related weight gain has been associated
with hyperinsulinemia (11).
Although the metabolic fate of VPA is similar in monkeys
compared with humans (43), there are several pharmacoki-
netic differences that need to be taken into account in this
study. VPA is eliminated more rapidly in the monkey, by a
10-fold higher metabolic clearance rate (19, 44). However,
monkeys have less drug-binding activity (less protein
bound) and higher free (active) drug levels compared with
the human at similar total plasma concentrations (10–15% in
humans vs. 46% in monkeys; Ref. 20). Peak plasma levels
were repeatedly measured at 2 h post dose and determined
to reach the therapeutic range. However, additional time
points throughout the day were not examined. A pharma-
cokinetic simulation suggested that levels were not likely
maintained within the therapeutic range throughout the 24-h
period. However, due to the use of equieffective dosing (16)
and decreased drug-binding capacity, it is likely that daily
exposure to free VPA concentrations in our monkeys was
comparable to human daily exposure from therapeutic doses.
In conclusion, our data suggest that, although effects on body
weight were observed, a long period of therapeutic exposure to
VPA did not induce cyclic hormonal or morphological abnor-
malities or hormonal characteristics of the PCOS when admin-
istered to nonepileptic normally cycling nonhuman primates.
These results do not support the hypothesis that VPA treatment
per se, at least of this duration, is entirely responsible for the
induction of PCOS in some women with epilepsy and bipolar
disease. This conclusion is evidently limited by the 12- to 15-
month length of treatment with VPA, compared with chronic
treatment in humans with epilepsy, and the fact that although
VPA levels reached the therapeutic range, these levels were not
FIG. 6. A whole-mount section of an ovary from monkey 53-124. This ovary was obtained during the luteal phase and contains a recent (mature)
corpus luteum and developing follicles at different stages. No subcortical fibrosis or superficial cortical cysts are seen.
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likely maintained within the therapeutic range throughout each
24-h period. Overall, the data suggest that VPA treatment by
itself may not be associated with the development of PCOS, but
rather the increased incidence of this syndrome in women with
epilepsy and bipolar disease may represent either a result of the
disorder or an interaction between a brain disorder and VPA,
which predisposes susceptible individuals to this syndrome.
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